Evaluation of Bronchodilator Prescription in Chronic Obstruction Pulmonary Disease Patients

Background: Chronic Obstructive Pulmonary Disease (COPD) is an irreversible, progressive chronic lung disease.

Aims: Evaluate the implementation of pharmacological therapy with bronchodilators in COPD patients at the Nursing Facility, Dr. Soehadi Prijonegoro Hospital, for the period January–December 2022, and compare it with the standard treatment of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

Methods: This study is a non-experimental descriptive study that is conducted retrospectively by looking at medical record data. Sampling is done using purposive sampling techniques, and there are 48 samples used based on the calculation of the Slovin formula. The data analysis included the accuracy of the use of bronchodilator drugs, the dosage precision of bronchodilator use, and the evaluation of prescriptions for bronchodilators compared to the 2022 GOLD standard.

Results: The results of the study showed that as much as 53% of patients were treated with single methylation parenterally, or β2 agonists, or antimuscarinics; 17% used multiple bronchodilator therapy with β2 combination Agonists; 12% used β2/corticosteroid combination therapy inhaler; and 17% used Agonis β2/anti-muscarin combination in nebulizer.

Conclusion: Bronchodilator prescriptions in COPD patients are 100% correct, 58.11% of the doses are correct, and the frequency of use of the drug is in line with the 2022 GOLD standard.